These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 713825)

  • 1. [L-dopa and prolactin in breast neoplasms and dysplasia].
    Moguilevsky L; Scacchi P; Szwarcfarb B; Barbarelli J; Moguilevsky JA
    Medicina (B Aires); 1978; 38(1):27-30. PubMed ID: 713825
    [No Abstract]   [Full Text] [Related]  

  • 2. [Determination of blood prolactin levels in breast diseases using prolactin radioimmunoassay kits (CIS-Prolak Kit)].
    Nakajima K; Saito K; Tobioka M; Ishihara K; Kobayashi T
    Horumon To Rinsho; 1976 Dec; 24(12):1303-10. PubMed ID: 1035518
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prolactin. Radioimmunoassay in female breast cancers and benign mastopathies].
    Gorins A; Netter A
    Nouv Presse Med; 1974 Jan; 3(2):73-5. PubMed ID: 4815434
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum prolactin level in healthy women and patients with functional disorders of the breast].
    Ozieblo L
    Endokrynol Pol; 1977; 28(4):323-30. PubMed ID: 891477
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma prolactin in breast cancer.
    Boyns AR; Cole EN; Griffiths K; Roberts MM; Buchan R; Wilson RG; Forrest AP
    Eur J Cancer (1965); 1973 Feb; 9(2):99-102. PubMed ID: 4717492
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours.
    Jones MK; Ramsay ID; Jenner PG
    Br J Clin Pharmacol; 1978 May; 5(5):425-30. PubMed ID: 656281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pituitary hormone level in breast cancer patients].
    Agranat VZ; Valiura AV; Nikogosian GA
    Med Radiol (Mosk); 1981 Mar; 26(3):3-8. PubMed ID: 6783807
    [No Abstract]   [Full Text] [Related]  

  • 8. Proceedings: Prolactin in benign and malignant breast disease.
    Cole EN; England PC; Sellwood RA; Griffiths K
    J Endocrinol; 1976 Jun; 69(3):49P-50P. PubMed ID: 950543
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum prolactin concentrations in benign breast disease throughout the menstrual cycle.
    Cole EN; Sellwood RA; England PC; Griffiths K
    Eur J Cancer (1965); 1977 Jun; 13(6):597-603. PubMed ID: 880967
    [No Abstract]   [Full Text] [Related]  

  • 10. The relationship of plasma prolactin to 17-B oestradiol in women with tumours of the breast.
    Jones MK; Ramsay ID; Collins WP; Dyer GI
    Eur J Cancer (1965); 1977 Oct; 13(10):1109-12. PubMed ID: 923610
    [No Abstract]   [Full Text] [Related]  

  • 11. Circadian mesor-hyperprolactinemia in fibrocystic mastopathy.
    Tarquini B; Gheri R; Romano S; Costa A; Cagnoni M; Lee JK; Halberg F
    Am J Med; 1979 Feb; 66(2):229-37. PubMed ID: 425966
    [No Abstract]   [Full Text] [Related]  

  • 12. Further evidence on the direct action of L-Dopa on prolactin release.
    Donoso AO; Banzán AM; Barcaglioni JC
    Neuroendocrinology; 1974; 15(3-4):236-9. PubMed ID: 4420786
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease.
    England PC; Sellwood RA; Knyba RE; Irvine JD
    Clin Oncol; 1981 Sep; 7(3):213-9. PubMed ID: 6211319
    [No Abstract]   [Full Text] [Related]  

  • 14. Breast cancer in a patient under levodopa treatment.
    Bozzetti F; Galante E; Costa A
    Tumori; 1978 Jun; 64(3):267-71. PubMed ID: 675856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dosage of prolactin in normal and pathological subjects (author's transl)].
    Franchimont P; Dourcy C; Legros JJ; Reuter A; Vrindts-Gevaert Y; van Cauwenberge JR; Remacle P; Gaspard U; Colin C
    Ann Endocrinol (Paris); 1976; 37(3):127-56. PubMed ID: 828474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of L-DOPA on serum prolactin in cases of galactorrhea-amenorrhea caused by a pituitary adenoma].
    Barreca T; Masturzo P; Rolandi E; Polleri A
    Boll Soc Ital Biol Sper; 1974 Nov; 50(21):1857-61. PubMed ID: 4477960
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prolactin and cancer of the breast. II. Prediction of the response to hormone treatment. The Minton test].
    Cueto Ladrón de Guevara J; García Puche JL; Pedraza V
    Rev Esp Oncol; 1985; 32(3):459-70. PubMed ID: 3870537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the dopa decarboxylase inhibitor MK-486 on L-dopa-induced inhibition of prolactin secretion: evidence for CNS participation in the L-dopa effects.
    Szabo M; Nakawatase C; Kovathana N; Frohman LA
    Neuroendocrinology; 1977; 24(1):24-34. PubMed ID: 600362
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of the treatment with an antiestrogen(tamoxifen) and levodopa on the secretion of prolactin in patients affected by breast cancer].
    Di Benedetto G; Gallamini A; Nizzo MC; Costa M; Indiveri F
    Boll Soc Ital Biol Sper; 1976 Oct; 52(19):1572-5. PubMed ID: 1024568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian variation of serum prolactin and TSH of women in health or with mammary carcinoma, fibroadenoma or fibrocystic mastopathy.
    Tarquini B; Gheri R; Romano S; Costa A; Cagnoni M; Lee JK; Halberg F
    Int J Chronobiol; 1980; 7(2):101-15. PubMed ID: 7450919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.